Avara, a contract manufacturing organization (CMO) with a global footprint to meet the diverse needs of pharmaceutical partners, offers capabilities including oral solid dose (OSD) manufacturing, sterile fill-finish, and integrated packaging.
 
The Norman, OK-based CMO maintains a network of established facilities offering capabilities, experience, and track records in supplying large-scale commercial products to global partners. These facilities maintain clean compliance records with major regulatory authorities, including the FDA, EMA, MHRA, PMDA, and ANVISA, serving over 40 markets worldwide.
 
The company’s OSD manufacturing capabilities encompass clinical and commercial-scale production of a diverse range of products, including potent compounds and targeted release formulations. Recent expansions include DEA licensing for controlled drugs, hot melt technology, and enhanced encapsulation capacity.
 
With a focus on aseptic liquid filling and sterile pharmaceutical manufacturing, Avara’s facility in Liscate, Italy, offers liquid and lyophilized fill-finish services for aseptic injectable products. Advanced capabilities, including terminal sterilization and containment for potent compounds, provide safe and efficient advancement of sterile drug products.
 
Avara provides end-to-end packaging solutions for OSD and sterile drug products, integrating primary and secondary packaging services, automated inspection, specialty packaging lines, and serialization to international standards.

“We provide personalized services to customers, ensuring access to senior management for comprehensive project tracking,” says Amit Arora, CEO of Avara. “Avara’s significant investments in quality underscore our commitment to regulatory compliance at all levels.”